AGM tidbits I missed the first few minutes of the start of the meeting, but what I picked up that was interesting from today's meeting.
- The board was re-elected.
- I believe Glenn Rourke stepped down
- The reason for the delay in the AVN Trials was due to the ethics committee. It's quite the process, and they must deal with the liability.
- Scale-up is Key, and they are in serious discussion with partners, but it all hinges on scale-up. That's why they brought on Michel Regnier. It was mentioned that Michel's objective is to focus on the scale-up. It was also noted that Michel might have some ideas on how to accelerate the process.
- The reason for the higher legal fees is that they are seriously looking to up moving to a different exchange by buying a company that's on an exchange already or additional products. In addition, Gilles highlighted the Biotech market is hurting, and they see this as an opportunity.
- Dr. Li will hold a virtual event explaining the outcome of the positive findings from the Avenanthramides. Gilles was pretty excited about the results.
Those were the main points from my point of view, and they align with prophet's.